Basis of Presentation, Summary of Significant Accounting Policies and Change in Accounting Principle - Additional Information (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2016	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		$ 40,416,000	$ 6,285,000
Non-current restricted investments		4,950,000	0
Non-current restricted cash		1,050,000	1,582,000
Total non-current restricted cash and restricted investments		6,000,000	1,582,000
Current restricted cash and restricted investments		34,416,000	4,703,000
Allowance for doubtful accounts receivable		0	0
Unbilled receivables		1,800,000	100,000
Research and development costs		11,100,000	5,800,000	$ 0
Goodwill impairment	$ 160,600,000	160,600,000	0	0
Equity method investment, other than temporary impairment		$ 0	0	$ 0
Vesting period		4 years
Expiration period		10 years
Collateral for letters of credit for facility leases
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		$ 4,852,000	3,710,000
Collateral with financial institutions
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		4,950,000	0
Pharmacy benefit management and claims processing services
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		30,555,000	2,479,000
Other
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		59,000	$ 96,000
Restricted Cash for Benefit Management Services, Client Relationship Established in 2016
Restricted Cash and Cash Equivalents Items [Line Items]
Total restricted cash and restricted investments		$ 27,000,000